Showing 2891-2900 of 4166 results for "".
- Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-dry-eye-disease/2477235/Neuroptika announced that the first patient was enrolled in a phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye diseas
- Lineage Provides Update on Patient Enrollment in Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry AMDhttps://modernod.com/news/lineage-provides-update-on-patient-enrollment-in-phase-1-2a-clinical-study-of-opregen-for-the-treatment-of-dry-amd/2477194/Lineage Cell Therapeutics announced additional patient data from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (AMD). The first Cohort 4 patient treated using bo
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- Iveric bio Initiating Second Pivotal Clinical Trial of Zimura in GA Secondary to Dry AMDhttps://modernod.com/news/iveric-bio-initiating-second-pivotal-clinical-trial-of-zimura-in-ga-with-1q-2020-targeted-for-first-patient-enrolled/2477090/Iveric bio provided further clinical details and its development strategy for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Based on the study design and the robustness of the rec
- Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol Eye Dropshttps://modernod.com/news/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops/2477075/Ocuphire Pharma announced statistically significant and clinically meaningful results from its recently completed two phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Topline results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmatory
- Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Diseasehttps://modernod.com/news/integrated-clinical-trial-analyses-further-substantiate-that-teprotumumab-significantly-improves-debilitating-effects-of-thyroid-eye-disease/2477063/Horizon Therapeutics announced integrated, pooled efficacy data from the phase 2 and phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulg
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne